By Fineline Cube 
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved the IND application for Abbisko’s investigational oral PD-L1 inhibitor, ABSK043, in combination with Allist’s KRAS G12C inhibitor, glecirasib, for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation.
Collaboration Background
In March 2025, Abbisko Therapeutics and Allist entered into a cooperation agreement to explore the potential of combining ABSK043 with glecirasib.
Drug Profiles
ABSK043 is a novel, oral, highly selective small-molecule PD-L1 inhibitor owned by Abbisko Therapeutics. Preclinical models have shown its anti-tumor efficacy to be on par with approved PD-L1 antibodies. Glecirasib (AST-24081), Allist’s KRAS G12C inhibitor, is currently being studied in multiple clinical trials for patients with advanced solid tumors harboring the KRAS G12C mutation. Notably, it has received orphan drug designation in the U.S. and breakthrough therapy designation in China for pancreatic cancer. In May 2025, the China NMPA approved glecirasib for market launch.-Fineline Info & Tech